Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?

about

Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?

Item

http://www.wikidata.org/entity/Q50096700

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Combination antiplatelet treat ...... il or an overzealous practice?

@en

Combination antiplatelet treat ...... il or an overzealous practice?

@nl

type

Item

label

Combination antiplatelet treat ...... il or an overzealous practice?

@en

Combination antiplatelet treat ...... il or an overzealous practice?

@nl

prefLabel

Combination antiplatelet treat ...... il or an overzealous practice?

@en

Combination antiplatelet treat ...... il or an overzealous practice?

@nl

P1476

Combination antiplatelet treat ...... il or an overzealous practice?

@en

P2093

Danai Sfantou

http://www.w3.org/2001/XMLSchema#string

Dimitrios Alexopoulos

http://www.w3.org/2001/XMLSchema#string

John Lekakis

http://www.w3.org/2001/XMLSchema#string

Konstantinos Katogiannis

http://www.w3.org/2001/XMLSchema#string

P2860

2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Vorapaxar in the secondary prevention of atherothrombotic events.

A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09537104.2017.1353685

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29022423

http://www.w3.org/2001/XMLSchema#string